Shamburg News · 8-K filed Nov 9, 2026, 7:30 AM EST

Inovio Pharmaceuticals Prices Public Offering of Common Stock and Pre-Funded Warrants

INO · INOVIO PHARMACEUTICALS, INC.

  • Financing
  • Material agreement
  • Reg FD disclosure
  • Other event
  • Materiality: high

On November 5, 2026, Inovio Pharmaceuticals entered into an underwriting agreement with Jefferies LLC and Piper Sandler & Co. for a public offering of 58,747,235 common shares at $1.05 per share and pre-funded warrants for up to 12,681,337 shares. On November 6, 2026, the underwriters exercised in full their option to purchase 10,714,285 additional shares. The company expects net proceeds of approximately $80.5 million, with closing on or about November 9, 2026, and believes these proceeds plus existing cash will fund operations into late fourth quarter 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 8.01, 9.01, accession 0001193125-26-452658.

Written from the filing by Shamburg Markets. Figures are as reported by the company.